Study details
Enrolling now
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Takeda
NCT IDNCT06100289ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
70
Study length
about 2.4 years
Ages
2–17
Locations
11 sites in CA, IL, MI +5
About this study
This trial is testing how the body processes vedolizumab, a drug given under the skin (SC), in children and teenagers with ulcerative colitis or Crohn's disease. Participants will receive vedolizumab for up to 34 weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Vedolizumab IV
- 2.Take Vedolizumab SC
PhasePhase 3
DrugVedolizumab IV
Routeinjection
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
vedolizumab
Drug routes
injection, intravenous, infusion
Body systems
Gastroenterology